Volume 24 Issue 5
May  2026
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2026  >  24(5): 812-815
TANG Yanping, SHAO Lei. Correlation between the variability of MMP family levels and the responsiveness to allergen-specific immunotherapy in children with allergic diseases[J]. Chinese Journal of General Practice, 2026, 24(5): 812-815. doi: 10.16766/j.cnki.issn.1674-4152.004497
Citation: TANG Yanping, SHAO Lei. Correlation between the variability of MMP family levels and the responsiveness to allergen-specific immunotherapy in children with allergic diseases[J]. Chinese Journal of General Practice, 2026, 24(5): 812-815. doi: 10.16766/j.cnki.issn.1674-4152.004497
shu

Correlation between the variability of MMP family levels and the responsiveness to allergen-specific immunotherapy in children with allergic diseases

doi: 10.16766/j.cnki.issn.1674-4152.004497

  • Department of Pediatrics, Chun'an Branch of Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 311700, China

Funds:

 2023XY014

  • Received Date: 2025-11-03
    Available Online: 2026-10-23
    Abstract
  •   Objective  MMPs can serve as biomarkers for early prediction of treatment efficacy of sublingual immunotherapy (SLIT) in children with allergic rhinitis (AR).However, whether they can be used to predict the efficacy of subcutaneous immunotherapy (SCIT) for allergen-specific therapy still requires further validation.Therefore, this study aims to investigate the correlation between the variability of matrix metalloproteinase (MMP) levels and the responsiveness of AR children to SCIT.  Methods  A total of 121 AR children admitted to the Chun'an Branch of Zhejiang Provincial People's Hospital from January 2021 to January 2022 were enrolled.All participants received a 3-year standard SCIT.Based on treatment responsiveness, children were categorized into effective and ineffective groups.Simultaneously, the variability of MMP levels was collected, and multivariate logistic regression analysis was employed to investigate its correlation with SCIT responsiveness.  Results  Among 121 children with AR who received treatment over a 3-year period, 3 failed to complete the full 3-year course and were therefore excluded.A total of 118 children were finally included in the analysis.Of these, 83 children achieved a reduction in the combined symptom and medication score (CSMS) of ≥30% and were classified into the effective group, while 35 children with a CSMS reduction of < 30% were assigned to the ineffective group.Multivariable logistic regression analysis showed that serum house dust mite-specific IgE levels, baseline MMP-9, baseline MMP-12, △MMP-9, and △MMP-12 were influencing factors associated with SCIT responsiveness in children with AR (all P < 0.05).The areas under the curve (AUCs) for predicting SCIT responsiveness were 0.733 for serum house dust mite-specific IgE, 0.738 for baseline MMP-9, 0.709 for baseline MMP-12, 0.706 for △MMP-9, 0.722 for △MMP-12, and 0.891 for the combined model.  Conclusion  Serum house dust mite-specific IgE levels, baseline MMP-9, baseline MMP-12, △MMP-9, and △MMP-12 levels are factors associated with 3-year SCIT responsiveness in children with AR.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组, 中华医学会耳鼻咽喉头颈外科学分会鼻科学组、小儿学组. 儿童变应性鼻炎诊断和治疗指南(2022年, 修订版)[J]. 中华耳鼻咽喉头颈外科杂志, 2022, 57(4): 392-404.

    Subspecialty Group of Rhinology, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery, Subspecialty Groups of Rhinology and Pediatrics, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association. Guideline for diagnosis and treatment of pediatric allergic rhinitis (2022, revision)[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2022, 57(4): 392-404.
    [2]
    中国医师协会变态反应医师分会, 中国医师协会儿科医师分会耳鼻咽喉专业委员会, 中国人体健康科技促进会儿童变态反应分会. 儿童过敏性鼻炎阶梯治疗中国专家共识[J]. 中华预防医学杂志, 2022, 56(9): 1182-1189.

    Allergy Branch of Chinese Medical Doctor Association Otolaryngology Group, Society of Pediatrics, Chinese Medical Doctor Association Child Allergy Professional Committee. Chinese expert consensus on stepwise treatment of pediatric allergic rhinitis[J]. Chinese Journal of Preventive Medicine, 2022, 56(9): 1182-1189.
    [3]
    ZHOU Y D, XU M, GONG W, et al. Circulating MMP-12 as potential biomarker in evaluating disease severity and efficacy of sublingual immunotherapy in allergic rhinitis[J]. Mediators Inflamm, 2022, 2022: 3378035. DOI: 10.1155/2022/3378035.
    [4]
    ZHU Y, ZHOU J, TANG R, et al. M2 macrophage-derived Apolipoprotein E promotes fibroblast MMPs expression via LRP1-ERK signaling in chronic rhinosinusitis with nasal polyps[J]. Mucosal Immunol, 2025, 18(5): 1171-1183. doi: 10.1016/j.mucimm.2025.07.004
    [5]
    ZHANG Y Q, SHUI J, WANG L, et al. Serum proteomics identifies S100A11 and MMP9 as novel biomarkers for predicting the early efficacy of sublingual immunotherapy in allergic rhinitis[J]. Int Immunopharmacol, 2023, 124(Pt A): 110857. DOI: 10.1016/j.intimp.2023.110857.
    [6]
    高永祥, 张晋昕. Logistic回归分析的样本量确定[J]. 循证医学, 2018, 18(2): 122-124.

    GAO Y X, ZHANG J X. Determination of Sample Size in Logistic Regression Analysis[J]. The Journal of Evidence-Based Medicine, 2018, 18(2): 122-124.
    [7]
    中国过敏性鼻炎研究协作组. 过敏性鼻炎皮下免疫治疗的临床操作规范[J]. 中国耳鼻咽喉头颈外科, 2018, 25(1): 1-12.

    Chinese Collaborative Group for Allergic Rhinitis Research. Clinical operational standards for subcutaneous immunotherapy in allergic rhinitis[J]. Chinese Archives of Otolaryngology-Head and Neck Surgery, 2018, 25(1): 1-12.
    [8]
    CRETICOS P S, GUNAYDIN F E, NOLTE H, et al. Allergen immunotherapy: the evidence supporting the efficacy and safety of subcutaneous immunotherapy and sublingual forms of immunotherapy for allergic rhinitis/conjunctivitis and asthma[J]. J Allergy Clin Immunol Pract, 2024, 12(6): 1415-1427. doi: 10.1016/j.jaip.2024.04.034
    [9]
    PARK M, KAPOOR S, YI J L, et al. Sublingual immunotherapy persistence and adherence in real-world settings: a systematic review[J]. Int Forum Allergy Rhinol, 2023, 13(5): 924-941. doi: 10.1002/alr.23086
    [10]
    尚虹, 邵磊, 胡崇伟. 过敏性鼻炎患儿变应原特异性免疫治疗前后炎症因子表达谱变化及其意义[J]. 中华全科医学, 2024, 22(9): 1555-1558. doi: 10.16766/j.cnki.issn.1674-4152.003681

    SHANG H, SHAO L, HU C W. Changes in inflammatory factors in children with allergic rhinitis before and after allergen-specific immunotherapy: expression spectrum and clinical significance[J]. Chinese Journal of General Practice, 2024, 22(9): 1555-1558. doi: 10.16766/j.cnki.issn.1674-4152.003681
    [11]
    KELSO J M. Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children[J]. Pediatrics, 2024, 154(Suppl 4): S29. DOI: 10.1542/peds.2024-069114IK.
    [12]
    LI H B, CHEN S, CHENG L, et al. Chinese guideline on sublingual immunotherapy for allergic rhinitis and asthma[J]. J Thorac Dis, 2019, 11(12): 4936-4950. doi: 10.21037/jtd.2019.12.37
    [13]
    PAN Y, ZHANG X X, GENG H T, et al. Increased nasal blimp1+treg cells after sublingual immunotherapy reflect the efficacy of treatment in allergic rhinitis[J]. Adv Ther, 2024, 41(4): 1698-1710. doi: 10.1007/s12325-024-02819-8
    [14]
    PYLE C J, PATEL D F, PEIRó T, et al. Matrix Metalloproteinase-12 supports pulmonary B cell follicle formation and local antibody responses during asthma[J]. Am J Respir Crit Care Med, 2022, 206(11): 1424-1428. doi: 10.1164/rccm.202109-2082LE
    [15]
    RAVANETTI L, DEKKER T, GUO L H, et al. Efficacy of FP-025: a novel matrix metalloproteinase-12 (MMP-12) inhibitor in murine allergic asthma[J]. Allergy, 2023, 78(2): 559-562. doi: 10.1111/all.15513
    [16]
    CHALISE U, BECIROVIC-AGIC M, KONFRST S R, et al. MMP-12 polarizes neutrophil signalome towards an apoptotic signature[J]. J Proteomics, 2022, 264: 104636. DOI: 10.1016/j.jprot.2022.104636.
    [17]
    SUN Y, TAM W K, ZHU M Y, et al. MMP12-dependent myofibroblast formation contributes to nucleus pulposus fibrosis[J]. JCI Insight, 2025, 10(7): e180809. DOI: 10.1172/jci.insight.180809.
    [18]
    CHIU K L, HE J L, CHEN G L, et al. Impacts of matrix metalloproteinase-9 promoter genotypes on asthma risk[J]. In Vivo, 2024, 38(5): 2144-2151. doi: 10.21873/invivo.13677
    [19]
    MING H, HUANG Y M, MAO J J, et al. Changes and clinical significance of serum MMP-9, TIMP-1, COX-2, and immune levels in patients with asthma[J]. Allergol Immunopathol (Madr), 2023, 51(6): 83-88. doi: 10.15586/v51i6.924
    [20]
    WANG N, SONG J, SUN S R, et al. Immune signatures predict response to house dust mite subcutaneous immunotherapy in patients with allergic rhinitis[J]. Allergy, 2024, 79(5): 1230-1241. doi: 10.1111/all.16068
    • Relative Articles
    • Supplements(0)
    • Cited By

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (11) PDF downloads(1) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return